STOCK TITAN

Fate Therapeutics (FATE) Stock News

FATE NASDAQ

Fate Therapeutics develops induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases. News about FATE centers on its off-the-shelf CAR T-cell and NK-cell product candidates, including FT819, FT836 and FT839, and on clinical or preclinical data presented at medical and cell-therapy meetings.

Recurring updates cover FT819 in systemic lupus erythematosus and other autoimmune diseases, next-generation CAR T programs for hematological malignancies and solid tumors, manufacturing and FDA CMC interactions, Regenerative Medicine Advanced Therapy designation, investor-conference participation, financial results, and Nasdaq employee inducement equity awards.

Rhea-AI Summary

Fate Therapeutics (FATE) reported responses in three lupus patients receiving FT819 without conditioning chemotherapy, including two who achieved remission.

All three extrarenal lupus patients responded: two achieved DORIS remission and one reached a low disease activity state. At the August 18, 2026 cutoff, 36 patients had received FT819 across three regimens, with no dose-limiting toxicities; 30 had at least three months of follow-up. Twelve received outpatient treatment, although one required hospitalization for cytokine release syndrome, an inflammatory reaction. The first two-dose patient reached low disease activity at Month 2, sustained at Month 3. Among six lupus nephritis patients, three achieved a complete or primary efficacy renal response at Month 6. The potentially registrational Phase 2 RECLAIM-LN study is ongoing. FT839 showed preclinical activity in rheumatoid arthritis models, and its Phase 1/2 COMPLETE trial is open for enrollment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.76%
Tags
none
-
Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) reported a third-quarter 2026 net loss of $30.7 million while advancing its autoimmune cell-therapy trials.

Loss per share was $0.25, versus $0.27 a year earlier. Cash and investments totaled $139.1 million at September 30, down $14.7 million quarterly and excluding a newly awarded $15.0 million CIRM grant. The company expects funding to last to mid-2028.

RECLAIM-LN, its potentially registrational Phase 2 lupus nephritis trial, has 17 active sites. Preliminary FT819 data showed renal responses in both bendamustine-treated patients with Month 6 follow-up; one patient's complete response persisted through Month 24. Across 29 autoimmune patients, severe infections occurred in two and severe blood-cell reductions in six. FT839 received FDA clearance to begin clinical testing, with multiple sites activated; Fate expects dosing by year-end. FT836 solid-tumor enrollment continues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.48%
Tags
-
Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) granted stock options and restricted stock units to newly hired non-executive employees on November 2, 2026. One employee received options to purchase 300,000 shares at $2.01 per share, matching the closing share price that day. Two employees, including the option recipient, received restricted stock units representing 87,000 shares.

Both awards vest over four years, subject to continued employment. Options vest 25% after one year, then in approximately equal monthly installments over thirty-six months. Restricted stock units vest 25% annually. The Compensation Committee approved the grants under the Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
none
Rhea-AI Summary

Fate Therapeutics (FATE) presented preliminary FT819 Phase 1 lupus nephritis data showing renal responses in both patients evaluable after bendamustine conditioning. At the August 18, 2026 cutoff, these patients achieved complete or primary efficacy renal responses at Month 6, with an approximately 50% mean reduction in urine protein-to-creatinine ratio, a measure of kidney damage. Immunosuppressants were discontinued; hydroxychloroquine and low-dose prednisone were permitted. One patient's complete response persisted through Month 24.

Across 29 autoimmune patients, no dose-limiting toxicity or deaths occurred. Low-grade cytokine release syndrome occurred in five patients; Grade ≥3 infections and low blood-cell counts occurred in two and six patients, respectively. The ongoing, potentially registrational Phase 2 RECLAIM-LN study uses the same bendamustine conditioning regimen in refractory, moderate-to-severe lupus with nephritis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
none
-
Rhea-AI Summary

Fate Therapeutics (FATE) appointed Jamie Harrell as Senior Vice President, Market Development & Commercial Operations, effective October 12, 2026.

In the newly created role, Harrell will lead commercial and market development strategy across the company's autoimmune disease and oncology programs. He will also shape physician engagement as Fate works toward commercialization. FT819 is being evaluated in RECLAIM-LN, a Phase 2 potentially registrational trial in refractory lupus nephritis. FT839 is in a Phase 1/2 trial across multiple autoimmune indications, including rheumatoid arthritis. Harrell most recently served as Vice President of Marketing and Commercial Operations at Aurinia Pharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
none
-
Rhea-AI Summary

Entera Bio (NASDAQ: ENTX) has appointed Laura Hamill to its Board of Directors, effective December 1, 2026, succeeding Yonatan Malca.

Hamill brings more than 35 years of global commercial, market access and business leadership experience. She most recently served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, leading approximately 2,500 employees responsible for $22 billion in annual revenue. Previously, she spent nearly two decades at Amgen, including overseeing commercial activities and supporting functions representing approximately 80% of Amgen’s revenue.

Entera expects her experience to support commercial preparedness for its osteoporosis candidate EB613 and broader pipeline advancement. Malca is stepping down after 16 years of service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
management
Rhea-AI Summary

Fate Therapeutics (FATE) granted equity inducement awards to two newly hired non-executive employees on October 1, 2026.

One employee received options to purchase 62,900 common shares at $2.30 per share, matching the Nasdaq closing price on the grant date. Two employees, including the option recipient, received restricted stock units (RSUs) representing 72,700 common shares. The Compensation Committee approved the awards under the Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4). Both award types vest over four years, subject to continued employment through each vesting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
Rhea-AI Summary

Fate Therapeutics (FATE) announced that management will participate in two investor conferences during the fourth quarter of 2026.

The Jefferies Global Healthcare Conference runs November 16–19 in London, UK, and the Piper Sandler 38th Annual Healthcare Conference runs December 1–3 in New York, NY. The company may participate in a presentation or fireside chat at these conferences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
none
-
Rhea-AI Summary

Fate Therapeutics (FATE) announced on September 25, 2026, that it received a $15.0 million grant for RECLAIM-LN. The California Institute for Regenerative Medicine (CIRM) awarded the funding through its CLIN2 program to support clinical development of the Phase 2, potentially registrational trial of FT819, an off-the-shelf CAR T-cell therapy.

RECLAIM-LN is studying FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis. The study will evaluate the treatment’s safety and efficacy. FT819 is designed to deplete pathological B cells; that intended effect is not a reported trial result.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
none
Rhea-AI Summary

Fate Therapeutics (FATE) will present four abstracts from its off-the-shelf, iPSC-derived CAR T-cell programs in autoimmune disease at ACR Convergence 2026 in Orlando, November 6-11, 2026.

Two presentations cover FT819, including updated clinical data on administration without conditioning chemotherapy, biomarker associations with quality-of-life improvement, and continued progress toward outpatient, community-based use. A third poster reports focus group findings on patient preferences for allogeneic CAR T-cell therapy in systemic lupus erythematosus. A fourth poster describes preclinical data and design progress for the COMPLETE Phase 1/2 trial of FT839, a dual-CAR T-cell candidate co-targeting CD19 and CD38 in rheumatoid arthritis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
none

FAQ

What is the current stock price of Fate Therapeutics (FATE)?

Fate Therapeutics (FATE) last closed at $1.14.

What is the market cap of Fate Therapeutics (FATE)?

The market cap of Fate Therapeutics (FATE) is approximately $138.7M.